It contains one Ig-like (immunoglobulin-like) domain and one ITAM domain. CD3E, along with CD3-gamma, CD3-delta, CD3-zeta, and T-cell receptor (TCR) alpha/beta or gamma/delta heterodimers ...

Although chimeric antigen receptor T-cell therapy has raised hopes for long-term remission in autoimmune disease, it has ...

In a new study on mice, an experimental antibody treatment reduced the lingering after-effects of head injuries.

Nasal anti-CD3 spray reduces traumatic brain injury in mice, a potential breakthrough for TBI treatment. Read now.

A treatment tested by researchers in Boston found it improves motor function, coordination and spatial memory in mice. But it ...

A recent groundbreaking study published in Nature has opened a promising new chapter in the treatment of traumatic brain ...

Fully human intranasal foralumab shows promise in treating Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS.

Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.

EpimAb_LogoPlanegg/Martinsried and Shanghai, February 27, 2025. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement ...

Accepted for Priority Review Linvoseltamab (GSK) B-cell maturation antigen CD3-targeted bispecific antibody Treatment of adult patients with relapsed/refractory multiple myeloma who have received ...

Immunotherapy. 2011;3(11):1303-1306. As discussed above, the proof-of-principle studies using both anti-CD3 antibodies (teplizumab and otelixizumab) showed effects on surrogate markers (C-peptide ...